Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

NCT04953962 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer Stage IV

Interventions

DRUG: CBP501 (16)
DRUG: CBP501 (25)
DRUG: Cisplatin
DRUG: Nivolumab

Sponsor

CanBas Co. Ltd.